Bryan Johnson Longevity Protocol: What Clinicians Should Tell Patients

Who Is Bryan Johnson and Why Are Patients Asking?

Bryan Johnson is a tech entrepreneur who sold Braintree/Venmo to PayPal for $800 million in 2013. He now dedicates the majority of his time and a reported $2 million per year to a personal longevity project he calls "Blueprint." His protocol is public. His biomarkers are public. His supplement list is public. Patients see him on podcasts, in Time magazine, and across social media, and they arrive in clinic asking whether they should follow his regimen.

The clinical obligation is not to validate or ridicule a celebrity's choices. The obligation is to give patients an accurate picture of what evidence exists, what risks are real, and what, if anything, from his protocol is appropriate to discuss for their specific situation.

How Blueprint Works

Johnson tracks roughly 70 biomarkers monthly, including lipid panels, hormone levels, inflammatory markers (hsCRP, IL-6), and epigenetic aging clocks such as DunedinPACE. He reports his results publicly on his website and in peer-reviewed correspondence. His stated goal is to achieve the biological metrics of an 18-year-old.

Diet provides the foundation. He eats three meals within a 6- to 9-hour window, finishing by 11 am. Total intake is approximately 1,977 kcal/day, sourced almost entirely from plants. Caloric restriction without malnutrition is among the best-studied longevity interventions in animal models; the CALERIE-2 trial (N=218) showed that 25% caloric restriction over 2 years reduced multiple aging biomarkers in non-obese humans, though the long-term benefit in already-lean individuals remains under study [1].

What He Publicly Reports Taking

Johnson's own published protocol lists (as of 2024) over 100 daily supplements and several prescription drugs. The prescription tier includes:

• Metformin 1,500 mg/day (extended-release)
• Rapamycin 13 mg weekly (intermittent dosing)
• Testosterone cypionate/enanthate (topical, physiologic replacement dosing)
• Tadalafil 5 mg/day
• DHEA 25 mg/day
• Acarbose 200 mg with meals

Each of these carries regulatory, safety, and evidence considerations that clinicians must understand before responding to patient questions.

Metformin for Longevity: What the Evidence Actually Shows

Metformin is an FDA-approved biguanide for type 2 diabetes mellitus [2]. Its potential longevity application rests on three mechanisms: AMPK activation, mTOR suppression, and a demonstrated association between metformin use and reduced all-cause mortality in observational cohorts of diabetic patients compared with matched non-diabetic controls.

The most-cited observational finding came from Bannister et al. (2014), who found that metformin-treated type 2 diabetes patients had longer survival than matched non-diabetic controls not taking metformin, suggesting a possible protective effect beyond glycemic control [3]. That finding generated enormous interest but cannot establish causation.

The TAME Trial

The Targeting Aging with Metformin (TAME) trial, a funded NIH study (NCT03351270) enrolling 3,000 adults aged 65-79 without diabetes, is the first prospective RCT designed to test metformin as an aging intervention [4]. Results are expected in the late 2020s. Until those data exist, prescribing metformin off-label to non-diabetic patients for longevity is not supported by guideline-level evidence from the American Diabetes Association or the Endocrine Society.

Risks Clinicians Must Communicate

Vitamin B12 malabsorption occurs in roughly 6-30% of patients on long-term metformin, depending on dose and duration [5]. Lactic acidosis risk, while rare, rises with renal impairment. Patients pursuing this off-label use need annual B12 monitoring, renal function checks, and a clear understanding that the FDA indication does not extend to healthy adults seeking longevity.

Rapamycin (Sirolimus): The mTOR Inhibitor in Johnson's Stack

Rapamycin is FDA-approved as an immunosuppressant for organ transplant recipients (Rapamune, Pfizer) [6]. Its proposed longevity mechanism involves inhibition of mTORC1, a nutrient-sensing pathway whose suppression extends lifespan in multiple model organisms. The landmark 2009 Harrison et al. Study in Nature showed that rapamycin started late in life extended median lifespan by 28% in male mice and 38% in female mice [7].

Translating mouse data to healthy humans is speculative. Johnson uses intermittent low-dose dosing (approximately 5-13 mg once weekly) based on the hypothesis that intermittent mTOR inhibition captures benefit while minimizing immunosuppression. This specific dosing strategy has no RCT support in healthy humans as of early 2025.

Known Adverse Effects

Even at low intermittent doses, rapamycin carries documented risks:

• Impaired wound healing
• Dyslipidemia (triglyceride and LDL elevations)
• Mouth sores (aphthous ulcers)
• Potential immune suppression, raising infection susceptibility
• Drug interactions via CYP3A4 (notably with azole antifungals and macrolide antibiotics)

The FDA label for sirolimus explicitly states it is not indicated outside transplant and select oncologic/vascular indications [6]. Off-label prescribing for longevity in healthy adults is occurring in some longevity medicine practices, but the Endocrine Society and AACE have not issued guideline support for this use.

The PEARL Trial

The PEARL trial (NCT04488016), a phase 2 RCT examining low-dose rapamycin in older adults, is among the few prospective studies in this space [8]. Clinicians and patients should be directed to that ongoing evidence base rather than uncontrolled self-experimentation.

Acarbose, Tadalafil, and DHEA: Evaluating the Rest of the Prescription Stack

Acarbose

Acarbose is an FDA-approved alpha-glucosidase inhibitor for type 2 diabetes [9]. Johnson uses it to blunt postprandial glucose spikes. The Interventions Testing Program (ITP), a National Institute on Aging-funded multi-site lifespan study in mice, found that acarbose extended median male mouse lifespan by 22% and female by 5% at high doses [10]. Again, mouse lifespan data do not translate automatically to humans. No RCT exists for acarbose as a longevity agent in non-diabetic humans.

Tadalafil

Tadalafil (Cialis) is FDA-approved for erectile dysfunction and benign prostatic hyperplasia [11]. Johnson uses 5 mg/day, the approved BPH dose, citing cardiovascular and endothelial benefits. Observational data suggest PDE5 inhibitor use may correlate with lower cardiovascular event rates, but no prospective longevity RCT exists for this indication.

DHEA

DHEA (dehydroepiandrosterone) is sold over the counter in the United States as a supplement and is not FDA-approved as a drug for any indication. Johnson reports using 25 mg/day in combination with testosterone. DHEA declines with age, and supplementation raises DHEA-S levels, but the clinical significance of that rise in healthy adults remains debated. A 2006 NEJM study (N=87, the "DHEA and Testosterone for Frailty" trial) found no significant benefit on muscle strength or body composition in older adults [12].

The Supplement Stack: 100-Plus Pills and the Evidence Problem

Johnson's publicly posted supplement list includes, among many others: NMN (nicotinamide mononucleotide), resveratrol, spermidine, lithium orotate (low dose), lycopene, vitamin D3 (2,000 IU), vitamin K2 (MK-7), omega-3 fatty acids, collagen peptides, and creatine monohydrate.

A few carry at least moderate evidence. Vitamin D3 supplementation reduces fracture risk and all-cause mortality in vitamin D-deficient adults; the 2022 VITAL trial (N=25,871) found no significant reduction in cancer or cardiovascular events in the general population, though a pre-specified subgroup of adults not taking supplements at baseline showed a 24% reduction in cancer mortality [13]. Omega-3 fatty acids at 4 g/day (prescription icosapentaenoic acid, specifically) reduced major cardiovascular events by 25% in the REDUCE-IT trial (N=8,179) in patients with elevated triglycerides on statins [14].

NMN and Resveratrol

NMN is marketed as a NAD+ precursor. A 12-week double-blind RCT published in Science (Yoshino et al., 2021, N=25 postmenopausal women with prediabetes) found NMN increased skeletal muscle insulin sensitivity and NMN-related metabolite levels but showed no significant body composition change [15]. Resveratrol's early promise in sirtuins research has not translated to consistent human benefit; a Cochrane-level systematic review found insufficient evidence to recommend resveratrol for any clinical indication [16].

Lithium Orotate (Low Dose)

Johnson reportedly takes approximately 1 mg/day of lithium orotate. This is dramatically below the therapeutic lithium dose range (typically 600-1,200 mg/day of lithium carbonate, targeting 0.6-1.2 mEq/L serum levels) used in bipolar disorder. Epidemiological data suggest that naturally occurring lithium in drinking water correlates inversely with suicide rates and dementia prevalence, but low-dose supplementation has not been tested in prospective longevity trials [17].

What Clinicians Should Actually Say to Patients

This is where the clinical conversation matters most. Patients drawn to Johnson's protocol are often highly motivated, health-literate, and frustrated with conventional medicine's limited longevity toolkit. Dismissing their interest damages rapport and misses a teaching opportunity.

A practical clinical framework for Blueprint-adjacent patient conversations has four steps:

Step 1. Acknowledge the evidence that does exist. Caloric restriction, structured exercise, high-quality sleep, and omega-3 supplementation (in the right patient) have genuine trial-level support. Johnson's adherence to sleep hygiene and daily exercise is not controversial and should be reinforced.

Step 2. Distinguish FDA-approved uses from off-label experimentation. Metformin in a pre-diabetic patient with metabolic syndrome has a defensible evidence base and is reflected in some guideline discussions. Metformin in a lean, normoglycemic 35-year-old purely for longevity does not. The TAME trial may change that calculus; for now, clinicians should be honest about the gap.

Step 3. Quantify individual risk before any prescription consideration. Rapamycin off-label use in a transplant-naive healthy adult carries immune suppression risk that may exceed any speculative benefit. Patients with a history of recurrent infections, immune-mediated conditions, or medication polypharmacy should hear a clear "the risk-benefit math does not favor this yet."

Step 4. Order the right baseline labs if the patient proceeds. If a patient is already using or strongly intends to use metformin off-label, ordering a baseline comprehensive metabolic panel, CBC, B12 level, and HbA1c is appropriate clinical management, not endorsement.

The Biological Age Clock Question

Patients also ask about DunedinPACE, GrimAge, and other methylation-based clocks that Johnson uses to track his protocol. These are commercially available from companies such as TruMe Health and Elysium. The Endocrine Society's 2023 scientific statement on biological aging noted that these clocks show "strong associations with incident disease and mortality in cohort studies" but are not yet validated as clinical management tools [18]. Ordering them for patients eager to quantify their aging trajectory is reasonable; making treatment decisions based solely on clock outputs is premature.

Diet and Exercise: The Underrated Core of Blueprint

Johnson's diet is a low-sugar, high-polyphenol, roughly 1,977 kcal/day vegan protocol he calls "The Blueprint Stack." He eats a large early-day meal (nicknamed "Super Veggie") combining black lentils, broccoli, cauliflower, mushrooms, garlic, ginger, and extra-virgin olive oil.

The Mediterranean dietary pattern, which shares substantial overlap with Johnson's food choices, remains among the most evidence-backed dietary interventions for cardiovascular and all-cause mortality reduction. The PREDIMED trial (N=7,447) found that a Mediterranean diet supplemented with either extra-virgin olive oil or nuts reduced major cardiovascular events by approximately 30% versus a low-fat control diet [19].

His exercise regimen includes Zone 2 aerobic training (approximately 45 minutes, 5 days per week), high-intensity intervals, and resistance training. The 2018 Physical Activity Guidelines Advisory Committee scientific report concluded that 150-300 minutes per week of moderate-intensity aerobic activity, plus muscle-strengthening on 2 or more days, significantly reduces all-cause mortality [20].

These two elements, a diet high in whole plant foods and a consistent structured exercise program, carry far more guideline-level evidence than any drug in Johnson's stack. Clinicians should name that explicitly.

Testosterone and Hormonal Interventions

Johnson has disclosed using topical testosterone at physiologic replacement doses. He is not a candidate for standard hypogonadism therapy by traditional thresholds (he reports normal testosterone levels), making this another off-label use aimed at optimizing rather than replacing a deficient hormone.

The Testosterone Trials (TTrials, N=788, 2016), published in NEJM, showed that testosterone treatment in men 65 and older with confirmed hypogonadism (total testosterone <275 ng/dL) improved sexual function, bone density, and anemia but showed no significant benefit on physical function or cognitive outcomes [21]. Extrapolating those findings to optimize already-normal testosterone in younger men is not supported by that trial's design or conclusions.

Clinicians should also be aware that exogenous testosterone, even topical, suppresses the hypothalamic-pituitary-gonadal axis and reduces endogenous production and fertility. Men of reproductive age considering testosterone optimization deserve a fertility-impact discussion before starting.

Risks of the Full Protocol as a Package

Most safety studies examine single interventions in isolation. Johnson's protocol stacks 100-plus compounds simultaneously. Clinicians should flag two categories of concern that are not speculative.

Pharmacokinetic Interactions

Rapamycin is a CYP3A4 substrate and P-glycoprotein inhibitor. Combining it with other CYP3A4-active supplements, which include compounds like berberine (a popular longevity supplement), creates unpredictable plasma level variability. The FDA drug interaction database and clinical pharmacology resources document dozens of interactions relevant to compounds on Johnson's published list [22].

Hormonal and Metabolic Crosstalk

Simultaneously suppressing mTOR (via rapamycin), activating AMPK (via metformin), reducing postprandial glucose (via acarbose), and supplementing anabolic hormones (testosterone, DHEA) creates overlapping and sometimes opposing hormonal signals. No clinical study has evaluated this combination in healthy adults. The interaction burden alone justifies cautious clinical oversight, not autonomous patient self-prescription.

FAQs